Generalized Arterial Calcification of Infancy (GACI): State of the Art and Clinical Perspectives

Area of Science:

• Genetics and rare diseases
• Cardiovascular medicine
• Biochemistry

Background:

• Generalized Arterial Calcification of Infancy (GACI) is a rare, severe autosomal recessive disorder.
• Characterized by pathological calcium deposition in arteries, leading to significant cardiovascular complications like hypertension, heart failure, and stroke.
• Untreated GACI has a high mortality rate, with approximately 50% of infants dying within six months of birth.

Purpose of the Study:

• To provide a comprehensive review of GACI, covering its pathophysiology, genetic basis, and clinical manifestations.
• To summarize current and emerging therapeutic strategies for GACI.
• To critically evaluate preclinical and early clinical evidence for enzyme replacement therapy (INZ-701) and discuss limitations.

Main Methods:

• Literature review of GACI pathophysiology, genetics, clinical features, and treatments.
• Analysis of preclinical and early clinical data for recombinant ENPP1 (INZ-701) therapy.
• Critical discussion of current therapeutic limitations and future directions.

Main Results:

• GACI is primarily caused by mutations in ENPP1 or ABCC6 genes, leading to inorganic pyrophosphate (PPi) deficiency.
• PPi is a crucial inhibitor of arterial calcification.
• Enzyme replacement therapy with recombinant ENPP1 (INZ-701) is an emerging strategy with early supporting evidence.

Conclusions:

• GACI is a life-threatening condition requiring effective therapeutic interventions.
• Understanding the genetic basis and pathophysiology is key to developing treatments.
• Recombinant ENPP1 (INZ-701) therapy represents a promising avenue, though further research and clinical validation are necessary.